Physiologically, preservation of C-peptide suggests that DPP-4 inhibitors may delay the autoimmune destruction of β-cells, a mechanism also observed in studies with GLP-1 agonists in patients with T1DM [11]. This evidence concerns the gene GLP1R and type 1 diabetes mellitus.